FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076953008> ?p ?o ?g. }

• W2076953008 endingPage "221" @default.
• W2076953008 startingPage "211" @default.
• W2076953008 abstract "Carcinosarcomas of the female genital tract are rare tumors with an aggressive clinical behavior. Trastuzumab, a humanized monoclonal antibody, acts by binding to HER2/neu extracellular domain and exhibits therapeutic efficacy in HER2/neu-overexpressing cancers. Two uterine carcinosarcomas (UMMT-ARK-1, UMMT-ARK-2) and 2 ovarian carcinosarcomas (OMMT-ARK-1, OMMT-ARK-2) were established as primary tumor cell lines in vitro and evaluated for HER2/neu expression by immunohistochemistry, fluorescent in situ hybridization analysis, quantitative real-time polymerase chain reaction, and for membrane-bound complement regulatory proteins CD46, CD55, and CD59 by flow cytometry. Sensitivity to trastuzumab-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity was studied in 5-hr chromium release assays. HER2/neu expression was demonstrated in OMMT-ARK-1 and OMMT-ARK-2. OMMT-ARK-2 demonstrated an amplification of the c-erbB2 gene by fluorescent in situ hybridization analysis and a high sensitivity to ADCC (mean killing, 45.6%; range, 32.3%–72.6%). A lower level of killing was detected against the fluorescent in situ hybridization analysis-negative OMMT-ARK-1 cell line (mean, 26.5%; range, 21.0%–31.8%). CD46, CD55, and CD59 membrane-bound complement regulatory proteins were expressed at high levels in all primary mixed müllerian tumor cell lines, and all these tumors were found to be highly resistant to complement-dependent cytotoxicity with or without trastuzumab. Addition of untreated and heat-inactivated plasma did not significantly decrease ADCC against OMMT-ARK-2 cell line, suggesting that while the cell line is highly resistant to complement, irrelevant IgG does not significantly alter the ability of trastuzumab to mediate ADCC. Our results suggest that HER2/neu may represent a novel target for the immunotherapy of a subset of human carcinosarcomas refractory to salvage chemotherapy." @default.
• W2076953008 created "2016-06-24" @default.
• W2076953008 creator A5008166734 @default.
• W2076953008 creator A5010339370 @default.
• W2076953008 creator A5021860051 @default.
• W2076953008 creator A5024732018 @default.
• W2076953008 creator A5026827320 @default.
• W2076953008 creator A5041993659 @default.
• W2076953008 creator A5046857977 @default.
• W2076953008 creator A5049383880 @default.
• W2076953008 creator A5061703014 @default.
• W2076953008 creator A5063469601 @default.
• W2076953008 creator A5063907350 @default.
• W2076953008 creator A5071283289 @default.
• W2076953008 creator A5074416196 @default.
• W2076953008 creator A5082726755 @default.
• W2076953008 creator A5087338346 @default.
• W2076953008 date "2012-05-01" @default.
• W2076953008 modified "2023-09-28" @default.
• W2076953008 title "HER2/neu as a Potential Target for Immunotherapy in Gynecologic Carcinosarcomas" @default.
• W2076953008 cites W1507909678 @default.
• W2076953008 cites W1963796410 @default.
• W2076953008 cites W1995118292 @default.
• W2076953008 cites W1996121307 @default.
• W2076953008 cites W1997056190 @default.
• W2076953008 cites W1999644056 @default.
• W2076953008 cites W2007738151 @default.
• W2076953008 cites W2009218955 @default.
• W2076953008 cites W2010690729 @default.
• W2076953008 cites W2016456933 @default.
• W2076953008 cites W2019658166 @default.
• W2076953008 cites W2023515204 @default.
• W2076953008 cites W2029330089 @default.
• W2076953008 cites W2039241242 @default.
• W2076953008 cites W2043144595 @default.
• W2076953008 cites W2046393549 @default.
• W2076953008 cites W2046551180 @default.
• W2076953008 cites W2055922116 @default.
• W2076953008 cites W2056941199 @default.
• W2076953008 cites W2057868041 @default.
• W2076953008 cites W2070783553 @default.
• W2076953008 cites W2072176789 @default.
• W2076953008 cites W2080588809 @default.
• W2076953008 cites W2088261664 @default.
• W2076953008 cites W2107426197 @default.
• W2076953008 cites W2131335059 @default.
• W2076953008 cites W2142287133 @default.
• W2076953008 cites W2142851253 @default.
• W2076953008 doi "https://doi.org/10.1097/pgp.0b013e31823bb24d" @default.
• W2076953008 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3366047" @default.
• W2076953008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22498937" @default.
• W2076953008 hasPublicationYear "2012" @default.
• W2076953008 type Work @default.
• W2076953008 sameAs 2076953008 @default.
• W2076953008 citedByCount "34" @default.
• W2076953008 countsByYear W20769530082012 @default.
• W2076953008 countsByYear W20769530082013 @default.
• W2076953008 countsByYear W20769530082014 @default.
• W2076953008 countsByYear W20769530082015 @default.
• W2076953008 countsByYear W20769530082016 @default.
• W2076953008 countsByYear W20769530082017 @default.
• W2076953008 countsByYear W20769530082019 @default.
• W2076953008 countsByYear W20769530082020 @default.
• W2076953008 countsByYear W20769530082021 @default.
• W2076953008 countsByYear W20769530082022 @default.
• W2076953008 countsByYear W20769530082023 @default.
• W2076953008 crossrefType "journal-article" @default.
• W2076953008 hasAuthorship W2076953008A5008166734 @default.
• W2076953008 hasAuthorship W2076953008A5010339370 @default.
• W2076953008 hasAuthorship W2076953008A5021860051 @default.
• W2076953008 hasAuthorship W2076953008A5024732018 @default.
• W2076953008 hasAuthorship W2076953008A5026827320 @default.
• W2076953008 hasAuthorship W2076953008A5041993659 @default.
• W2076953008 hasAuthorship W2076953008A5046857977 @default.
• W2076953008 hasAuthorship W2076953008A5049383880 @default.
• W2076953008 hasAuthorship W2076953008A5061703014 @default.
• W2076953008 hasAuthorship W2076953008A5063469601 @default.
• W2076953008 hasAuthorship W2076953008A5063907350 @default.
• W2076953008 hasAuthorship W2076953008A5071283289 @default.
• W2076953008 hasAuthorship W2076953008A5074416196 @default.
• W2076953008 hasAuthorship W2076953008A5082726755 @default.
• W2076953008 hasAuthorship W2076953008A5087338346 @default.
• W2076953008 hasBestOaLocation W20769530082 @default.
• W2076953008 hasConcept C109316439 @default.
• W2076953008 hasConcept C111684460 @default.
• W2076953008 hasConcept C142724271 @default.
• W2076953008 hasConcept C153911025 @default.
• W2076953008 hasConcept C159654299 @default.
• W2076953008 hasConcept C184404459 @default.
• W2076953008 hasConcept C202751555 @default.
• W2076953008 hasConcept C203014093 @default.
• W2076953008 hasConcept C40677261 @default.
• W2076953008 hasConcept C502942594 @default.
• W2076953008 hasConcept C542903549 @default.
• W2076953008 hasConcept C54355233 @default.
• W2076953008 hasConcept C553184892 @default.
• W2076953008 hasConcept C55493867 @default.
• W2076953008 hasConcept C71924100 @default.

• next